Hyderabad, India based Natco Pharma Limited announced today that it has launched the first generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, Inc., under brand name Epclusa®.
Epclusa® is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin.
Natco will market Sofosbuvir 400mg/Velpatasvir 100mg under the brand name VELPANAT®. Natco priced its generic medicine of VELPANAT at an MRP of INR 25,000/- equivalent for a bottle of 28 tablets in Nepal. Natco has signed a non-exclusive licensing agreement with Gilead Sciences, Inc., to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.
3 thoughts on “Hepatitis C generic drug, Velpanat, launched in Nepal”
Can I get location where I can buy in Nepal any contact number if it’s possible
Can you please provide me location or contact person in Nepal ?
I had hep c, genotype 3 for years with my viral load over 6 million. The doctor prescribed to take Epclusa but i was very worried because my insurance rejected then someone told me about generic epclusa. I was afraid to take it that it’ll help or not but I had no other choice so I bought generic epclusa “Velpanat” from medixocentre.com . I took this med for 30 days with very minimal side effects over a year ago. I’m extremely proud to say it worked! I’m cured! I did a blood test. I can’t say enough good things about this drug! It truly saved my life. Good luck on your journey. I hope it does the same for everyone that needs it.” Highly recommend this drug!